|
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
|
Mar 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Common polymorphic deletion of glutathione S-transferase theta predisposes to acquired aplastic anemia: Independent cohort and meta-analysis of 609 patients.
|
Jun 2013
|
Am J Hematol
|
aplastic anemia
|
|
Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
|
Aug 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.
|
Oct 2013
|
Am J Hematol
|
aplastic anemia
|
|
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
|
Oct 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
|
May 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
